Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance

Behavioural Brain Research

Volumn 207, Issue 1, 2010, Pages 118-124

  Briody, Siobhan ^a   Boules, Mona ^a   Oliveros, Alfredo ^a   Fauq, Irfan ^a   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

Clozapine; Haloperidol; Neurotensin; Prepulse inhibition; Tolerance

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; CLOZAPINE; DEXAMPHETAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTENSIN 69L; NEUROTENSIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; HUMAN; HYPERACTIVITY; NONHUMAN; PATHOPHYSIOLOGY; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION; STARTLE REFLEX; STEREOTYPY;

ACOUSTIC STIMULATION; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG TOLERANCE; HALOPERIDOL; NEUROTENSIN; PEPTIDE FRAGMENTS; RATS; SENSORY GATING;

EID: 70649101230     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.09.044     Document Type: Article

References (60)

1. Alexander M.J., and Leeman S.E. Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor. J Comp Neurol 402 (1998) 475-500
2. Allen G.V., and Cechetto D.F. Neurotensin in the lateral hypothalamic area: origin and function. Neuroscience 69 (1995) 533-544
3. Andersen M.P., and Pouzet B. Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats. Psychopharmacology (Berl) 156 (2001) 291-304
4. Auclair A.L., Kleven M.S., Besnard J., Depoortere R., and Newman-Tancredi A. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 31 (2006) 1900-1909
5. Binder E.B., Kinkead B., Owens M.J., and Nemeroff C.B. Neurotensin and dopamine interactions. Pharmacol Rev 53 (2001) 453-486
6. Bissette G., Nemeroff C.B., Loosen P.T., Prange A.J., and Lipton M.A. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature 262 (1976) 607-609
7. Boudin H., Grauz-Guyon A., Faure M.P., Forgez P., Lhiaubet A.M., Dennis M., Beaudet A., Rostene W., and Pelaprat D. Immunological recognition of different forms of the neurotensin receptor in transfected cells and rat brain. Biochem J 305 (1995) 277-283
8. Boules M., Fredrickson P., and Richelson E. Current topics: brain penetrating neurotensin analog. Life Sci 73 (2003) 2785-2792
9. Boules M., Fredrickson P., and Richelson E. Neurotensin agonists as an alternative to antipsychotics. Expert Opin Investig Drugs 14 (2005) 359-369
10. Boules M., McMahon B., Wang R., Warrington L., Stewart J., Yerbury S., Fauq A., McCormick D., and Richelson E. Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier. Brain Res 987 (2003) 39-48
11. Boules M., Shaw A., Fredrickson P., and Richelson E. Neurotensin agonists: potential in the treatment of schizophrenia. CNS Drugs 21 (2007) 13-23
12. Boules M., Warrington L., Fauq A., McCormick D., and Richelson E. A novel neurotensin analog blocks cocaine- and d-amphetamine-induced hyperactivity. Eur J Pharmacol 426 (2001) 73-76
13. Braff D., Stone C., Callaway E., Geyer M., Glick I., and Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15 (1978) 339-343
14. Braff D.L., Grillon C., and Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49 (1992) 206-215
15. Castellanos F.X., Fine E.J., Kaysen D., Marsh W.L., Rapoport J.L., and Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry 39 (1996) 33-41
16. Chalon P., Vita N., Kaghad M., Guillemot M., Bonnin J., Delpech B., Le Fur G., Ferrara P., and Caput D. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett 386 (1996) 91-94
17. Consensus R. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
18. Cooper J.R., Bloom F.E., and Roth RH. The biochemical basis of neuropharmacology (1996), Oxford University Press, NY pp. 310-43
19. Cusack B., Boules M., Tyler B.M., Fauq A., McCormick D.J., and Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res 856 (2000) 48-54
20. Drumheller A.D., Gagne M.A., St-Pierre S., and Jolicoeur F.B. Effects of neurotensin on regional brain concentrations of dopamine, serotonin and their main metabolites. Neuropeptides 15 (1990) 169-178
21. Dubuc I., Pain C., Suaudeau C., and Costentin J. Tolerance to the hypothermic but not to the analgesic effect of [d-Trp11]neurotensin during the semichronic intracerebroventricular infusion of the peptide in rats. Peptides 15 (1994) 303-307
22. Emson P.C., Goedert M., Horsfield P., Rioux F., and St Pierre S. The regional distribution and chromatographic characterisation of neurotensin-like immunoreactivity in the rat central nervous system. J Neurochem 38 (1982) 992-999
23. Fauq A.H., Hong F., Cusack B., Tyler B.M., Pang Y.P., and Richelson E. Synthesis of (2S)-2-amino-3-(1H-4-indolyl) propanoic acid, a novel trryptophan analog for structural modification of bioactive peptides. Tetrahedron: Asymmetry 9 (1998) 4127-4134
24. Feifel D., Melendez G., Murray R.J., Tina Tran D.N., Rullan M.A., and Shilling P.D. The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. Psychopharmacology (Berl) 200 (2008) 197-203
25. Feifel D., Melendez G., and Shilling P.D. A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist. Neuropsychopharmacology 28 (2003) 651-653
26. Feifel D., Melendez G., and Shilling P.D. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology 29 (2004) 731-738
27. Feifel D., Reza T.L., Wustrow D.J., and Davis M.D. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther 288 (1999) 710-713
28. Geyer M.A., and Swerdlowr N.R. Measurement of startle response, prepulse inhibition, and habituation. In: Crawley J.N., Gerfen C.R., McKay R., Rogawski M.A., Sibley D.R., and Skolnick P. (Eds). Current protocols in neuroscience (1998), Wiley, New York 8.7.1-8.7.15
29. Hadden M.K., Orwig K.S., Kokko K.P., Mazella J., and Dix T.A. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. Neuropharmacology 49 (2005) 1149-1159
30. Hertel P., Byskov L., Didriksen M., and Arnt J. Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity. Eur J Pharm 422 (2001) 77-81
31. Hertel P., Olsen C.K., and Arnt J. Repeated administration of the neurotensin analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour. Eur J Pharmacol 439 (2002) 107-111
32. Jolas T., and Aghajanian G.K. Neurotensin and the serotonergic system. Prog Neurobiol 52 (1997) 455-468
33. Kinkead B., Binder E.B., and Nemeroff C.B. Does neurotensin mediate the effects of antipsychotic drugs?. Biol Psychiatry 46 (1999) 340-351
34. Lieberman J.A. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUTLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 63 (2006) 1069-1072
35. Lieberman J.A., and Koreen A.R. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 19 (1993) 371-429
36. Mai J.K., Triepel J., and Metz J. Neurotensin in the human brain. Neuroscience 22 (1987) 499-524
37. Malendowicz L.K., and Miskowiak B. Effects of prolonged administration of neurotensin, arginine-vasopressin, NPY, and bombesin on blood TSH, T3 and T4 levels in the rat. In Vivo 4 (1990) 259-261
38. Mazella J., Botto J.M., Guillemare E., Coppola T., Sarret P., and Vincent J.P. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J Neurosci 16 (1996) 5613-5620
39. Morilak D.A., Garlow S.J., and Ciaranello R.D. Immunocytochemical localization and description of neurons expressing serotonin2 receptors in the rat brain. Neuroscience 54 (1993) 701-717
40. Nemeroff C.B., Bissette G., Prange A.J., Loosen P.T., Barlow T.S., and Lipton M.A. Neurotensin: central nervous system effects of a hypothalamic peptide. Brain Res 128 (1977) 485-496
41. Nemeroff C.B., Hernandez D.E., Luttinger D., Kalivas P.W., and Prange A.J. Interactions of neurotensin with brain dopamine systems. Ann NY Acad Sci 400 (1982) 330-344
42. Nemeroff C.B., Levant B., Myers B., and Bissette G. Neurotensin, antipsychotic drugs, and schizophrenia. Basic and clinical studies. Ann NY Acad Sci 668 (1992) 146-156
43. Nicot A., Rowe W.B., De Kloet E.R., Betancur C., Jessop D.S., Lightman S.L., Quirion R., Rostene W., and Berod A. Endogenous neurotensin regulates hypothalamic-pituitary-adrenal axis activity and peptidergic neurons in the rat hypothalamic paraventricular nucleus. J Neuroendocrinol 9 (1997) 263-269
44. Rang H.P., Dale M.M., Ritter J.M., and Gardner P. Pharmacology (2003), Churchill Livingstone, Elsevier Science Limited pp. 19-21
45. Rowe W., Viau V., Meaney M.J., and Quirion R. Central administration of neurotensin stimulates hypothalamic-pituitary-adrenal activity. The paraventricular CRF neuron as a critical site of action. Ann NY Acad Sci 668 (1992) 365-367
46. Secchi R.L., Sung E., Hedley L.R., Button D., and Schreiber R. The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist but not by dopaminergic agonists. Behav Brain Res 202 (2009) 192-197
47. Shilling P.D.M.G., Priebe K., Richelson E., and Feifel D. Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT(2A) and an alpha(1) agonist. Psychopharmacology (Berl) 175 (2004) 353-359
48. Shilling P.D., Richelson E., and Feifel D. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behav Brain Res 143 (2003) 7-14
49. Sipes T.E., and Geyer M.A. DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Brain Res 761 (1997) 97-104
50. Swerdlow N.R., Benbow C.H., Zisook S., Geyer M.A., and Braff D.L. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry 33 (1993) 298-301
51. Swerdlow N.R., and Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24 (1998) 285-301
52. Swerdlow N.R., Paulsen J., Braff D.L., Butters N., Geyer M.A., and Swenson M.R. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry 58 (1995) 192-200
53. Tamminga C.A. Practical treatment information for schizophrenia. Am J Psychiatry 163 (2006) 563-565
54. Tanaka K., Masu M., and Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron 4 (1990) 847-854
55. Tyler-McMahon B.M., Stewart J.A., Farinas F., McCormick D.J., and Richelson E. Highly potent neurotensin analog that causes hypothermia and antinociception. Eur J Pharmacol 390 (2000) 107-111
56. Ungerstedt U., and Ljungberg T. Behavioral patterns related to dopamine neurotransmission: effect of acute and chronic antipsychotic drugs. Adv Biochem Psychopharmacol 16 (1977) 193-199
57. Vita N., Laurent P., Lefort S., Chalon P., Dumont X., Kaghad M., et al. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett 317 (1993) 39-42
58. Wang R., Boules M., Tiner W., and Richelson E. Effects of repeated injections of the neurotensin analog NT69L on dopamine release and uptake in rat striatum in vitro. Brain Res 1025 (2004) 21-28
59. Wang R., Boules M., Gollatz E., Williams K., Tiner W., and Richelson E. Effects of 5 daily injections of the neurotensin-mimetic NT69L on the expression of neurotensin receptors in rat brain. Brain Res Mol Brain Res 138 (2005) 24-34
60. Zhang J., Forkstam C., Engel J.A., and Svensson L. Role of dopamine in prepulse inhibition of acoustic startle. Psychopharmacology (Berl) 149 (2000) 181-188